What is the official ID of this bill?

The official print number for this legislation is HR 5850.

When did the legislative process begin?

The process officially started on 2023-09-29.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/hr5850/BILLS-118hr5850ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Who is the primary sponsor?

The primary sponsor is Rep. Mann, Tracey [R-KS-1].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Analysis and Potential Impact of HR 5850

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Nullifying mifepristone access changes and prohibiting federal funding.

Q: What are the main provisions?

Key points include: Nullifies FDA modifications from January 3, 2023, concerning mifepristone, potentially impacting its availability. Prohibits federal funding for establishing, implementing, or enforcing new, similar mifepristone regulations.

This bill aims to reverse modifications made by the Food and Drug Administration (FDA) regarding the use of mifepristone. This could mean that access to this medication would revert to previous regulations. Additionally, the bill prohibits the use of federal funds to implement or enforce new, similar rules concerning mifepristone.

Key points

Nullifies FDA modifications from January 3, 2023, concerning mifepristone, potentially impacting its availability.

Prohibits federal funding for establishing, implementing, or enforcing new, similar mifepristone regulations.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Print number: HR 5850

Sponsor: Rep. Mann, Tracey [R-KS-1]

Process start date: 2023-09-29

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Nullifying mifepristone access changes and prohibiting federal funding.

Key Questions about Nullifying mifepristone access changes and prohibiting federal funding.